Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 26.35 | 81.84 | 21.32 | — | 11.05 | 7.22 | 20.86 | 20.89 | 18.22 | 14.49 | 19.97 | 37.83 | — | 17.50 | 26.03 | 18.27 | 8.51 | 7.04 | 25.56 | 23.99 | 31.87 |
| — | +1033.9% | +2.2% | — | -39.4% | -50.2% | +4.5% | -44.8% | — | -17.2% | -23.3% | +107.1% | — | +148.5% | +1.9% | -23.9% | -73.3% | -75.7% | -1.7% | -9.1% | +100.4% | |
| P/S Ratio | 3.50 | 2.94 | 2.74 | 2.83 | 2.10 | 1.73 | 2.05 | 2.28 | 2.87 | 3.43 | 3.43 | 3.95 | 3.68 | 4.22 | 4.10 | 3.95 | 3.85 | 2.88 | 3.07 | 3.24 | 3.78 |
| — | +69.5% | +33.7% | +24.5% | -26.8% | -49.5% | -40.2% | -42.4% | -22.0% | -18.7% | -16.2% | -0.0% | -4.6% | +46.5% | +33.5% | +22.1% | +1.8% | -38.5% | -22.4% | -2.1% | +14.6% | |
| P/B Ratio | 1.87 | 1.70 | 1.46 | 1.41 | 1.13 | 1.04 | 1.18 | 1.34 | 1.73 | 2.13 | 2.07 | 2.55 | 2.57 | 2.87 | 2.93 | 3.00 | 3.03 | 2.51 | 2.77 | 3.23 | 3.86 |
| — | +64.0% | +24.0% | +5.8% | -34.5% | -51.2% | -43.1% | -47.5% | -32.7% | -25.7% | -29.4% | -15.2% | -15.1% | +14.0% | +5.7% | -7.0% | -21.6% | -45.8% | -30.7% | -8.5% | -6.9% | |
| P/FCF | 16.76 | 16.40 | 9.76 | 11.61 | 4.20 | 31.75 | 23.52 | 8.04 | 8.78 | 14.50 | 18.19 | — | 18.43 | 25.90 | 25.96 | — | 16.06 | 10.68 | 74.79 | 11.49 | 14.14 |
| — | -48.3% | -58.5% | +44.4% | -52.1% | +119.0% | +29.3% | — | -52.4% | -44.0% | -29.9% | — | +14.8% | +142.5% | -65.3% | — | +13.6% | -5.0% | +375.0% | — | +39.2% | |
| EV / EBITDA | 13.62 | 53.96 | 14.23 | 24.91 | 7.15 | 7.08 | 6.55 | 9.59 | 10.93 | 18.35 | 11.14 | 16.85 | 23.91 | 14.07 | 16.05 | 16.00 | 10.50 | 8.10 | 13.83 | 15.87 | 12.90 |
| — | +662.1% | +117.3% | +159.6% | -34.6% | -61.4% | -41.2% | -43.1% | -54.3% | +30.5% | -30.6% | +5.3% | +127.7% | +73.6% | +16.1% | +0.8% | -18.6% | -67.1% | +21.4% | — | +23.4% | |
| EV / EBIT | 20.41 | 45.64 | 18.21 | — | 9.34 | 6.05 | 8.79 | 13.10 | 15.63 | 11.91 | 14.76 | 23.85 | 39.41 | 17.93 | 21.30 | 16.82 | 12.62 | 9.57 | 14.38 | 17.60 | 14.64 |
| — | +654.4% | +107.1% | — | -40.3% | -49.2% | -40.4% | -45.1% | -60.3% | -33.6% | -30.7% | +41.8% | +212.4% | +87.3% | +48.1% | -4.5% | -13.8% | -66.7% | +15.5% | — | +23.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.5% | 56.9% | 73.3% | 78.2% | 64.3% | 64.2% | 76.2% | 76.2% | 74.1% | 61.2% | 78.3% | 74.1% | 73.9% | 75.9% | 73.1% | 77.6% | 81.3% | 81.3% | 70.2% | 75.9% | 81.6% |
| — | -11.4% | -3.8% | +2.6% | -13.2% | +4.9% | -2.6% | +2.9% | +0.2% | -19.3% | +7.1% | -4.5% | -9.0% | -6.7% | +4.1% | +2.2% | -0.4% | -2.6% | -14.6% | -8.4% | -5.9% | |
| Operating Margin | 19.1% | 11.6% | 16.0% | -2.5% | 25.0% | 22.2% | 30.1% | 20.7% | 23.4% | 14.9% | 30.1% | 21.5% | 12.7% | 28.1% | 23.3% | 21.9% | 34.7% | 36.2% | 20.7% | 18.5% | 28.8% |
| — | -47.7% | -46.8% | -112.1% | +6.8% | +49.5% | -0.0% | -3.4% | +84.6% | -47.1% | +29.2% | -2.2% | -63.4% | -22.4% | +12.6% | +18.4% | +20.5% | +113.2% | -42.7% | +260.0% | -10.6% | |
| Net Margin | 13.2% | 3.6% | 12.9% | -2.1% | 19.0% | 24.0% | 9.9% | 10.9% | 15.8% | 23.7% | 17.2% | 10.5% | -2.7% | 24.1% | 15.7% | 21.6% | 45.2% | 40.9% | 12.0% | 13.5% | 11.8% |
| — | -85.1% | +30.3% | -119.5% | +20.6% | +1.3% | -42.4% | +3.8% | +685.4% | -1.7% | +9.1% | -51.6% | -105.9% | -41.1% | +31.2% | +60.6% | +281.8% | +152.8% | -21.2% | +7.3% | -43.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.4% | 0.5% | 1.7% | -0.3% | 2.6% | 3.7% | 1.4% | 1.6% | 2.4% | 3.8% | 2.6% | 1.7% | -0.5% | 4.2% | 2.9% | 4.2% | 9.2% | 9.2% | 2.7% | 3.4% | 3.0% |
| — | -85.8% | +21.3% | -116.5% | +8.0% | -2.3% | -45.5% | -5.5% | +612.0% | -10.4% | -8.2% | -59.5% | -105.1% | -54.3% | +4.2% | +24.8% | +209.2% | +123.6% | -28.7% | +0.9% | -53.2% | |
| ROA | 4.5% | 0.3% | 1.1% | -0.2% | 1.6% | 2.3% | 0.9% | 0.9% | 1.4% | 2.2% | 1.5% | 0.9% | -0.3% | 2.4% | 1.6% | 2.2% | 4.5% | 4.3% | 1.3% | 1.5% | 1.4% |
| — | -85.9% | +26.4% | -117.4% | +15.0% | +3.0% | -41.8% | +4.3% | +652.2% | -8.0% | -6.7% | -59.3% | -105.6% | -45.3% | +23.4% | +44.3% | +233.2% | +134.1% | -24.4% | +6.9% | -51.0% | |
| ROIC | 6.5% | 1.0% | 1.4% | -0.2% | 2.2% | 2.1% | 2.6% | 1.8% | 2.1% | 1.3% | 2.5% | 1.9% | 1.3% | 2.9% | 2.5% | 2.6% | 4.0% | 4.2% | 2.4% | 2.3% | 3.5% |
| — | -51.9% | -48.3% | -111.0% | +5.2% | +57.6% | +6.6% | -3.7% | +64.4% | -54.2% | -2.9% | -27.7% | -68.7% | -30.7% | +7.2% | +13.4% | +14.1% | +101.1% | -44.7% | +254.6% | -28.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.44 | 0.35 | 0.38 | 0.36 | 0.37 | 0.39 | 0.40 | 0.41 | 0.42 | 0.46 | 0.50 | 0.53 | 0.46 | 0.48 | 0.49 | 0.52 | 0.64 | 0.68 | 0.69 | 0.70 |
| — | +18.5% | -9.8% | -4.1% | -11.0% | -10.8% | -14.6% | -20.0% | -23.7% | -8.0% | -4.8% | +0.4% | +2.5% | -28.4% | -29.1% | -28.8% | -25.8% | -6.5% | -5.7% | -5.3% | -4.0% | |
| Debt / EBITDA | 2.47 | 46.01 | 12.29 | 23.26 | 8.08 | 8.43 | 7.23 | 9.57 | 8.75 | 12.68 | 8.29 | 11.25 | 17.31 | 8.16 | 9.63 | 9.75 | 6.70 | 7.05 | 11.37 | 11.85 | 8.17 |
| — | +445.9% | +70.0% | +143.1% | -7.7% | -33.5% | -12.8% | -14.9% | -49.4% | +55.3% | -13.9% | +15.3% | +158.4% | +15.8% | -15.3% | -17.7% | -18.0% | -45.7% | +60.0% | — | +25.2% | |
| Current Ratio | 2.68 | 1.87 | 3.06 | 2.68 | 2.72 | 2.50 | 1.44 | 1.35 | 1.26 | 2.29 | 2.10 | 2.00 | 1.68 | 3.27 | 3.24 | 2.99 | 2.49 | 1.94 | 2.01 | 1.83 | 1.70 |
| — | -25.5% | +112.9% | +98.7% | +115.7% | +9.4% | -31.3% | -32.5% | -25.2% | -30.1% | -35.3% | -33.2% | -32.3% | +68.6% | +61.4% | +63.7% | +46.3% | -9.6% | -5.5% | -0.7% | -17.5% | |
| Quick Ratio | 2.03 | 1.26 | 2.41 | 2.03 | 2.04 | 1.79 | 1.01 | 0.90 | 0.80 | 1.48 | 1.32 | 1.26 | 1.09 | 2.86 | 2.81 | 2.58 | 2.14 | 1.68 | 1.70 | 1.51 | 1.38 |
| — | -29.7% | +139.0% | +124.9% | +154.3% | +20.8% | -23.2% | -28.4% | -26.2% | -48.1% | -53.2% | -51.1% | -49.0% | +69.6% | +65.7% | +70.5% | +54.8% | -5.0% | -3.1% | -2.7% | -22.9% | |
| Interest Coverage | 8.80 | 2.61 | 6.17 | -2.13 | 9.27 | 12.61 | 11.37 | 8.46 | 8.89 | 13.21 | 9.14 | 6.45 | 4.24 | 12.90 | 8.28 | 11.77 | 13.77 | 13.78 | 9.71 | 8.72 | 12.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIIB stock.
Biogen Inc.'s current P/E is 26.3x. The average P/E over the last 3 quarters is 38.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Biogen Inc.'s current operating margin is 19.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Biogen Inc.'s business trajectory between earnings reports.